曼恩凯德生物医疗 MNKD 深 沪
已收盘 10-31 16:00:00 美东时间
5.59
+0.040
+0.72%
华盛通- 最 高5.655
- 今 开5.51
- 成交量 341.14万股
- 最 低 5.46
- 昨 收 5.55
- 总市值 17.16亿
- 52周最高 7.48
- 市盈率 静 57.51
- 换手率 1.11%
- 52周最低 3.3812
- 委 比 -48.91%
- 总股本 3.07亿
- 历史最高 57.40
- 量 比 0.83
- 振 幅 3.51%
- 历史最低 0.666
- 每 手 1
- 风险率 1.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MannKind's Afrezza under supplemental FDA review
MannKind Corporation (MNKD) announced that the U.S. FDA has accepted the supplemental marketing application seeking approval for Afrezza (insulin human) inhalation powder in children and adolescents l...
10-13 21:43
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
MannKind Corporation announced that the FDA has accepted its sBLA seeking approval for Afrezza (insulin human) Inhalation Powder for children and adolescents with type 1 or type 2 diabetes. The submission is based on data from the Phase 3 INHALE-1 study and has a PDUFA target action date of May 29, 2026. If approved, Afrezza would be the first needle-free insulin option for pediatric patients in over 100 years of insulin therapy. The study evalua...
10-13 12:05
MannKind Completes Acquisition of scPharma
MannKind ( ($MNKD) ) just unveiled an announcement. On October 7, 2025, MannKin...
10-10 05:53
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
MannKind Corporation successfully completed its acquisition of scPharmaceuticals Inc., enhancing its product portfolio with FUROSCIX® and expanding its reach in cardiometabolic care. The deal diversifies MannKind's revenue, expected to exceed $370 million annually, and strengthens its commercial and medical capabilities. The transaction includes a tender offer valued at up to $6.35 per share, with scPharmaceuticals becoming a wholly owned subsidi...
10-07 13:00
Mannkind names Dr. Ajay Ahuja chief medical officer
MannKind Corporation has appointed Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer, effective immediately. Dr. Ahuja will report directly to Michael Castagna, PharmD, the CEO. ...
09-29 18:19
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
MannKind Corporation has appointed Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective immediately. Dr. Ahuja brings over 20 years of leadership experience in the biopharmaceutical industry, including roles at Kardigan Bio, Idorsia Pharmaceuticals, and Allergan. With expertise in medical affairs, clinical development, and global strategy, particularly in cardiometabolic areas, Dr. Ahuja is expected to significantly contribute to MannKind's p...
09-29 10:05
scPharmaceuticals Issues Promissory Note to MannKind
The latest update is out from scPharmaceuticals ( ($SCPH) ). On September 23, 2...
09-25 16:25
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRY, SCPH, WKHS on Behalf of Shareholders
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/o...
09-22 20:46
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $11 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates MannKind (NASDAQ:MNKD) with a Buy and maintains $11 price target.
09-18 18:17
